Paindrainer AB was founded at Medicon Village in Lund by Prof. Carl Borrebaeck, Dr. Maria Rosén Klement and Mr Göran Barkfors.
The first beta-version ready for clinical studies
The first clinical study in co-operation with University of California San Diego Health was finished and published with highly encouraging outcomes.
Clinical studies with Newton-Wellesley Hospital in Boston and Weill Cornell Medicine in New York fortifies Paindrainer's clinical evidence.
The multi-center study is published in Pain Medicine.
Paindrainer is registered as a class I medical device with the FDA.
A public version is released and wins The Nordic Health App Award 2023. First commercial partnership secured in the U.S.
Partnership established with esteemed Bragée Clinics in Sweden.
European Patent Office (EPO) grants patent for the unique patient-centric concept. Clinical study initiated at Cleveland Clinic.
In 2017, Professor Carl Borrebaeck and Doctor Maria Rosén Klement worked together at Lund University in Sweden. Dr. Klement, who herself experiences chronic pain, had participated in a chronic pain rehabilitation programs where she observed that all program attendees faced a similar challenge. Namely, the level of pain varied daily and was influenced by sleep patterns and daily activities. Dr. Klement recognized that pain is influenced by numerous parameters beyond what the human brain can reasonably track. She shared her insights with Prof. Borrebaeck, noting that advanced calculations could potentially calculate these parameters and aid in pain management.
Subsequently, Dr. Klement and Prof. Borrebaeck enlisted the expertise of IT specialist Göran Barkfors to investigate the feasibility of leveraging machine learning, or artificial intelligence, to help individuals with chronic pain better comprehend their pain and improve their quality of life.
The goal was to create a tool that empowers individuals with chronic, non-malignant pain to comprehend the impact of various activities, and combinations of activities, on their pain levels, thereby enabling them to take charge of their pain management. The Paindrainer digital tool was developed.
In the spring of 2021, a pilot study of Paindrainer was conducted, yielding highly encouraging outcomes. Patients with chronic pain who participated in the study reported improved quality of life and alleviated pain levels after only six weeks of using Paindrainer.
The realization of this vision was made possible through the support of investors, pain management experts, and individuals with chronic pain, who shared the passion and belief of Dr. Klement, Prof. Borrebaeck, and Mr. Barkfors in the potential of their idea to enhance the lives of millions of individuals living with chronic pain.
Erik Frick
CEO
[email protected]
+1 646 979 8319
We are here to help. You are welcome to contact us and we'll get back to you.
Leading hospitals and pain specialists in Scandinavia and in USA have contributed to the development of the Medical Device product. Thank you for your support.
Here you can find common questions and answers. If you're missing any answers, don't hesitate to contact us. We're here to help you!